Xenon will replace Copaxone

Discussion in 'Teva Neuroscience' started by Anonymous, Jul 3, 2015 at 10:51 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Jerusalem, and Burnaby, British Columbia (December 11, 2012) — Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and Xenon Pharmaceuticals Inc. (Xenon) announced today that they have entered into a collaborative development and exclusive worldwide license for XEN402. XEN402 is currently in clinical development for a variety of painful disorders. This product specifically targets sodium channels which are abundantly found in sensory nerve endings that can increase in chronic painful conditions. Under the Agreement, Teva will pay Xenon an upfront fee of $41 million. In addition Teva shall pay development, regulatory, and sales-based milestones totaling up to $335M. Xenon is entitled to royalties payable on sales and an option to participate in commercialization in the U.S.
     

  2. Anonymous

    Anonymous Guest

    Or maybe not?????
     
  3. Anonymous

    Anonymous Guest

    Yeah, years-old news. I hate to be a doomsayer, but start brushing up on your resume and interviewing skills. CNS is probably going to start seeing some mass layoffs once the 3 times a week copaxone dries up on conversions
     
  4. Anonymous

    Anonymous Guest

    Teva and Xenon Provide Update on TV-45070 Phase 2b Study in Osteoarthritis Pain

    • TV-45070 4% and 8% did not demonstrate statistically significant difference from placebo in efficacy endpoints in Phase 2b study in pain due to osteoarthritis of the knee.
    • TV-45070 demonstrated a favorable safety and tolerability profile, with no drug-related serious adverse events.
    • Low drug plasma levels coupled with the favorable tolerability profile support the topical application rationale and continued development in neuropathic pain.
    • Teva and Xenon remain fully committed to the development of TV-45070 for neuropathic pain indications and await the results from the ongoing PHN Phase 2b study, expected in the second half of 2016.